InterAx Biotech Ltd and Alveus Therapeutics Inc. have entered into a strategic research collaboration and licensing agreement aimed at developing a differentiated small-molecule therapy for metabolic disease, with an initial focus on delivering durable weight loss while improving tolerability compared with existing treatments.
Under the agreement, the two companies will jointly advance a novel therapeutic candidate that targets a well-established but underexplored biological pathway. The collaboration brings together InterAx’s proprietary Deep Signal™ discovery platform and Alveus’s extensive research and development expertise in obesity, diabetes, and cardiometabolic disorders. Financial terms of the deal were not disclosed, but the agreement includes an upfront payment to InterAx and the potential for additional development, regulatory, and commercial milestone payments.
The partnership comes at a time of intense global interest in obesity and metabolic disease treatments, driven by rising prevalence rates and the commercial success of newer weight-loss drugs. While current therapies have demonstrated strong efficacy, they can be associated with tolerability challenges and limitations in long-term adherence. InterAx and Alveus aim to address these gaps by designing a small-molecule candidate optimized for more favorable signaling behavior, potentially offering sustained benefits with fewer side effects.
InterAx’s Deep Signal™ platform is designed to decode and optimize complex G protein-coupled receptor (GPCR) signaling, a class of targets that underpins many metabolic pathways. By integrating drug chemistry, protein structure, cellular signaling, and functional efficacy, the platform seeks to identify compounds with superior therapeutic profiles rather than relying solely on traditional measures of target activation.
Andrew Roberts, Chief Executive Officer of InterAx, said the collaboration represents a significant step forward in translating the company’s platform into meaningful clinical impact. He noted that combining Deep Signal™ with Alveus’s metabolic disease expertise creates a strong foundation for advancing a highly differentiated candidate intended to overcome some of the shortcomings of today’s obesity medications.
Alveus, a company focused on developing next-generation therapies for cardiometabolic diseases, will contribute its deep translational and clinical development capabilities. Jacob Jeppesen, Chief Scientific Officer and Head of R&D at Alveus, highlighted the complementary nature of the partnership, emphasizing that InterAx’s integrated approach to drug design aligns well with Alveus’s goal of efficiently advancing innovative, best-in-class metabolic therapies.
Together, the companies plan to progress the joint research program through preclinical development, with the longer-term objective of delivering a novel treatment option for patients with obesity and related metabolic conditions. If successful, the collaboration could add a new entrant to the rapidly evolving metabolic disease landscape, offering patients an alternative designed for both effectiveness and improved tolerability.